On Sept. 8, 2022, a clinical trial evaluating alternative strategies for administering the JYNNEOS mpox vaccine to increase the number of available doses began enrolling adult volunteers.

The trial planned to enroll more than 200 adults across eight U.S. research sites, and was sponsored by the National Institute of Allergy and Infectious Diseases.